Patents by Inventor Saeed Moshashaee
Saeed Moshashaee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220373249Abstract: Containers are provided herein for facilitating freezing, thawing, and/or storage of products that may be perishable, such as pharmaceuticals. The containers can include shells that enclose the product, and that include apertures permitting flow of a fluid through the containers' internal volume. The temperature of the fluid can be selected so as to freeze or thaw the product. The container optionally can include pressure building members that control the flow of the fluid through the containers' inner volume, e.g., increase the fluid flow rate and thus increase the rate with which the fluid is frozen or thawed.Type: ApplicationFiled: November 13, 2020Publication date: November 24, 2022Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Richard WISNIEWSKI, Saeed MOSHASHAEE, Pooja SANE
-
Publication number: 20220251526Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lyso-somal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.Type: ApplicationFiled: April 25, 2022Publication date: August 11, 2022Inventors: SAEED MOSHASHAEE, JASON K. PINKSTAFF, ADAM SHAYWITZ, NATALIE CIACCIO
-
Patent number: 11345904Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.Type: GrantFiled: February 24, 2017Date of Patent: May 31, 2022Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Saeed Moshashaee, Jason K. Pinkstaff, Adam Shaywitz, Natalie Ciaccio
-
Patent number: 11229687Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: GrantFiled: July 28, 2020Date of Patent: January 25, 2022Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Thomas Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O'Neill
-
Publication number: 20200353059Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: ApplicationFiled: July 28, 2020Publication date: November 12, 2020Inventors: Thomas Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O'Neill
-
Publication number: 20200297821Abstract: The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals.Type: ApplicationFiled: February 24, 2017Publication date: September 24, 2020Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: SAEED MOSHASHAEE, JASON K. PINKSTAFF, ADAM SHAYWITZ, NATALIE CIACCIO
-
Patent number: 10758598Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: GrantFiled: March 28, 2019Date of Patent: September 1, 2020Assignee: BioMarin Pharmaceutical Inc.Inventors: Thomas Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O'Neill
-
Publication number: 20190216905Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: ApplicationFiled: March 28, 2019Publication date: July 18, 2019Inventors: Thomas Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O'Neill
-
Patent number: 10279015Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: GrantFiled: May 5, 2016Date of Patent: May 7, 2019Assignee: BioMarin Pharmaceutical Inc.Inventors: Thomas W. Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O'Neill
-
Publication number: 20160324942Abstract: Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.Type: ApplicationFiled: May 5, 2016Publication date: November 10, 2016Inventors: Thomas W. Lester, Saeed Moshashaee, Augustus O. Okhamafe, Charles A. O' Neill
-
Patent number: 7829123Abstract: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.Type: GrantFiled: September 15, 2006Date of Patent: November 9, 2010Assignee: AstraZeneca ABInventors: Goran Eric Sundholm, Mustafa Demirbuker, Saeed Moshashaee
-
Publication number: 20070009604Abstract: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.Type: ApplicationFiled: September 15, 2006Publication date: January 11, 2007Inventors: Goran Sundholm, Mustafa Demirbuker, Saeed Moshashaee
-
Patent number: 7108867Abstract: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.Type: GrantFiled: January 21, 2002Date of Patent: September 19, 2006Assignee: Astrazeneca ABInventors: Goran Eric Sundholm, Mustafa Demirbuker, Saeed Moshashaee
-
Publication number: 20040058007Abstract: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid comprising a fluid gas and an organic solvent using an anti-solvent fluid gas technique under conditions of temperature and pressure which result in the precipitation of particles comprising the substance, wherein the temperature of the first liquid is at or above the cloud point temperature of the first liquid when the first liquid contacts the second liquid. Also claimed are particles obtained according to the process and compositions containing the particles.Type: ApplicationFiled: July 8, 2003Publication date: March 25, 2004Inventors: Goran Eric Sundholm, Mustafa Demirbuker, Saeed Moshashaee
-
Patent number: 6475524Abstract: The invention provides a process for crystallization of amorphous and/or meta-stable crystalline regions of preformed particles by treating the particles with a supercritical or subcritical fluid containing an anti-solvent and a solvent. The invention further provides formulations comprising particles produced according to the present process containing one or more pharmacologically active substances and one or more pharmaceutically acceptable excipients, use of said formulations in the treatment of an allergic and/or inflammatory condition of the nose or lungs and methods for treatment of such conditions.Type: GrantFiled: March 1, 2000Date of Patent: November 5, 2002Assignee: AstraZeneca ABInventors: Mikael Bisrat, Saeed Moshashaee, Håkan Nyqvist, Mustafa Demirbüker
-
Patent number: 6468994Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterized in that they are substantially smooth and having a BET value of from 1 to 4.5 m2/g, a process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of respiratory disorder, and a method of treatment of respiratory disorders by administration of said particles to a host in need of such treatment.Type: GrantFiled: November 6, 2001Date of Patent: October 22, 2002Assignee: AstraZeneca ABInventors: Mikael Bisrat, Saeed Moshashaee
-
Patent number: 6461642Abstract: The invention provides a process for preparing essentially crystalline particles containing a substance in solvated form, by dissolving the substance in a first solvent, introducing the solution and a supercritical or subcritical fluid into an apparatus, wherein the fluid contains an anti-solvent and a second solvent, which is water. Preferably, the anti-solvent is carbon dioxide which is totally saturated with the second solvent, which is water. The invention further provides formulations comprising particles produced according to the present process containing one or more pharmacologically active substances and one or more pharmaceu-tically acceptable excipients, use of said formulations in the treatment of an allergic and/or inflammatory condition of the nose or lungs and methods for treatment of such conditions.Type: GrantFiled: March 1, 2000Date of Patent: October 8, 2002Assignee: AstraZeneca ABInventors: Mikael Bisrat, Saeed Moshashaee, Håkan Nyqvist, Mustafa Demirbüker
-
Publication number: 20020037257Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterised in that they are substantially smooth and having a BET value from 1 to 4.5 m2/g, process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of a respiratory disorder, and a method of treatment of respiratory disorders by administration, to a host in need of such treatment, said particles.Type: ApplicationFiled: November 6, 2001Publication date: March 28, 2002Applicant: AstraZeneca AB, a Swedish corporationInventors: Mikael Bisrat, Saeed Moshashaee
-
Patent number: 6346523Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterized in that they are substantially smooth and having a BET value from 1 to 4.5 m2/g, process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of a respiratory disorder, and a method of treatment of respiratory disorders by administration of said particles to a host in need of such treatment.Type: GrantFiled: June 18, 1998Date of Patent: February 12, 2002Assignee: AstraZeneca ABInventors: Mikael Bisrat, Saeed Moshashaee